{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-007983","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2023-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.106987+00:00","generated_at":"2026-06-18T02:09:05.227261+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Prelude Therapeutics reports FY 2022 net loss of $115.4M; cash runway through Q4 2024","bullets":["Net loss of $115.4M ($2.44 per share) vs $111.7M ($2.43 per share) in FY 2021.","Cash and equivalents of $201.7M as of Dec 31, 2022; runway extended through Q4 2024.","R&D expenses $92.9M, G&A $30.7M; both up YoY.","Clinical trial collaboration with BeiGene to evaluate PRT2527 + zanubrutinib in hematologic malignancies.","Bryant D. Lim appointed Chief Legal Officer, effective Feb 20, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-007983","json":"https://secwatch.observer/filing/0000950170-23-007983.json","markdown":"https://secwatch.observer/filing/0000950170-23-007983.md","text":"https://secwatch.observer/filing/0000950170-23-007983.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000095017023007983/0000950170-23-007983-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000095017023007983/prld-20230315.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T02:09:05.227261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5f34fc11588f256280430ddd35f619eb098e9d86","claim":"Prelude Therapeutics Inc reported financial results for fiscal year ended December 31, 2022.","evidence_excerpt":"On March 15, 2023, Prelude Therapeutics Incorporated (the \"Company\") issued a press release announcing its financial results for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1678660/000095017023007983/0000950170-23-007983-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}